1-4 of 4
Tania Curcio
Close
Sort by
Journal Articles

Phase II Trial of SGI-110 (Guadecitabine) in Philadelphia Negative Myeloproliferative Neoplasms

Pinkal Desai, MDMPH, Niamh Savage, BA, Spencer Krichevsky, BS, Tania Curcio, Sangmin Lee, MD, Michael B. Samuel, MD, Ellen K. Ritchie, MD, Gail J. Roboz, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1666.
https://doi.org/10.1182/blood-2019-127663
Published: 2019
Journal Articles

CPX-351 As First Intensive Therapy for Elderly Patients with AML

Ellen K. Ritchie, MD, Sumaiya K. Miah, BA, Sangmin Lee, MD, Tania Curcio, Pinkal Desai, MDMPH, Jeffrey Ball, MD, Michael B. Samuel, MD, Gail J. Roboz, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3858.
https://doi.org/10.1182/blood-2019-130263
Published: 2019
Journal Articles

Changes in Gut Microbial Diversity and Correlations with Clinical Outcomes in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Receiving Intensive Chemotherapy

Sangmin Lee, MD, Ellen K. Ritchie, MD, Sumaiya Miah, Caroline Andy, Tania Curcio, Finola Goudy, Michael Hovan, Claire Douglass, Pinkal Desai, MDMPH, Michael B. Samuel, MD, Gail J. Roboz, MD, Michael Satlin, MD, M.S.
Journal: Blood
Blood (2019) 134 (Supplement_1): 1336.
https://doi.org/10.1182/blood-2019-125441
Published: 2019
Journal Articles

Minimal Residual Disease (MRD) As Exploratory Endpoint in a Phase 1 Study of the Anti-CD123 Mab CSL362 Given As Post-Remission Therapy in Adult Acute Myeloid Leukemia (AML)

B. Douglas Smith, MD, Andrew W. Roberts, MBBS, PhD, Gail J. Roboz, MD, Mark DeWitte, VMD, Anna Ferguson, BSN, RN, Linda Garrett, RN, Tania Curcio, Kaysey F. Orlowski, Sue Dasen, MS, Debra M. Bensen-Kennedy, MD, Roland B. Walter, MD PhD MS
Journal: Blood
Blood (2015) 126 (23): 3819.
https://doi.org/10.1182/blood.V126.23.3819.3819
Published: 2015